NICE final draft "no" for Sanofi's Jevtana
In final draft guidance, the National Institute for Health and Clinical Excellence (NICE) says it does not recommend Sanofi's Jevtana (cabazitaxel), in combination with prednisone or prednisolone, as a second-line treatment for prostate cancer. ...
NICE rejects Sanofi's Jevtana
Negative NICE guidance for Sanofi prostate cancer drug
Sanofi's Jevtana Cancer Drug Rejected by UK Cost Agency